FIGURE 5.

Continual administration of Pimavanserin has a sustained effect on ISF Aβ. Young APP/PS1 mice has baseline ISF Aβ₄₀ measured by in vivo microdialysis for 8 hr followed by implantation of an Alzet osmotic pump subcutaneously on the back to continually administer vehicle or Pimavanserin at 3 mg kg day⁻¹ or 6 mg kg day⁻¹. Aβ gradually declined to reach new, sustained levels of 40.4 ± 2.0% (p = .001) and 39.5 ± 4.9% (p = .003) in the treatment groups, respectively, by 36–48 hr after pump implantation compared to vehicle-treated mice (n = 3–5 mice per group). Data present as mean ± SEM